Francois Cedric, chief executive officer of Apellis Pharmaceuticals (APLS), has filed 39 Form 4 disclosures with a pronounced sell-side bias. Across all reported transactions, Cedric has recorded approximately $10.54 million in open-market sales, with zero corresponding purchases or acquisitions. The most recent cluster of filings, dated May 14, 2026, consists almost entirely of code "D" transactions—sales back to the issuer—alongside several code "A" grants and code "U" entries, all valued at $0. This pattern indicates that his recent activity is dominated by compensation-related events and share returns rather than discretionary market moves.
The absence of any open-market purchase (code "P") in his entire filing history is notable for a CEO, as such transactions are typically viewed as the clearest signal of insider conviction. Instead, Cedric's realized selling has been the sole cash-generating activity, with the aggregate $10.54 million in sales spread across his tenure. The May 14 filings, while numerous, carry no dollar value, suggesting they reflect administrative adjustments—such as shares surrendered to cover tax obligations or vesting mechanics—rather than active portfolio decisions. The heavy concentration of "D" codes on that date, paired with "A" grants, points to a routine equity compensation cycle rather than a strategic exit.
For investors tracking insider behavior, Cedric's record is unambiguous: he has been a net seller over time, with no recent buying to offset that trend. The lack of any purchase activity, combined with the mechanical nature of his latest filings, leaves the sell-side bias intact. While the $10.54 million total is modest relative to a typical biotech CEO's holdings, the consistency of the pattern—sales without any counterbalancing buys—offers a clear, if not dramatic, signal of his transactional posture in APLS shares.
AI-assisted summary